AbstractPart 1. Troglitazone analogues as cyclin D1 ablative agents: the potential drugs for breast cancer therapy. Cyclin D1 overexpression has been implicated in oncogene-induced
mammary tumorigenesis as it is detected in over 50% of primary
breast carcinomas and is correlated with poor prognosis. It has been reported that troglitazone (TG), a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, can induce degradation of cyclin D1 as part of its mechanism for causing cell cycle arrest and growth inhibition in breast cancer cells. In this study, we obtained evidence that the ability of high doses of TG to repress cyclin D1 is independent of PPARγ activation.
